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Introduction
Myelodysplastic syndromes (MDS) are diseases of complex and varied biology manifested clinically by ineffective and dysplastic hematopoiesis. In a subset of patients, an immune mechanism has been implicated in disease pathobiology (1, 2) . Historically, patients with suspected immune-mediated MDS and aplastic anemia (AA) have been treated with equine(e)anti-thymocyte globulin (e-ATG) with and without cyclosporine-A (CsA) (3) (4) (5) (6) . Combined treatment with e-ATG and etanercept (7, 8) as well as alemtuzumab monotherapy (9) have shown activity in a subset of MDS patients with lower International Prognostic Scoring System (IPSS) risk and specific selection criteria including younger age, shorter duration of red cell transfusion requirements, and HLA-DR15 genotype (1, 10, 11) . In a series of 129 unselected MDS patients treated at the National Institutes of Health (NIH), responses to e-ATG plus CsA led to durable hematologic improvement in 30% of patients, with improvement in overall survival and progression-free survival in patients with low or intermediate IPSS risk disease compared to historical outcomes in the International MDS Risk Analysis Workshop (IMRAW) database (1) . Although a similar response rate of 29% was observed in a recent randomized phase 3 trial, that study failed to show an overall survival benefit or improvement in event free survival in e-ATG+CsA-treated patients compared to best supportive care (BSC) (12) . The latter finding may relate to the cross-over design allowing treatment of patients on BSC and the inadequate statistical power to assess survival advantage. Wide spread acceptance of immunosuppressive therapy (IST) has proven difficult owing to conflicting reports regarding efficacy and safety in unselected MDS patients, unfamiliarity of community hematologist with this modality and lack of cohesive criteria for patient selection (13) .
In addition to e-ATG, rabbit ATG(r-ATG) has also shown activity in patients with AA and in small cohorts of patients with MDS (14) (15) (16) . Although e-ATG is associated with superior response rates in AA (17) , phase II studies in MDS have demonstrated similar rates of response in r-ATG-treated patients. Delineating the underlying pathophysiology in patients responsive to IST, development of cohesive selection criteria based on biological features, and optimizing treatment regimens are all key to adoption of this therapy for those MDS patients most likely to benefit. To this end, we performed a multicenter phase 2 trial to investigate the efficacy and safety of r-ATG in low or intermediate IPSS risk MDS patients, and analyzed pretreatment clinical variables associated with response. Combined data from this study and a second cohort of patients treated with e-ATG was analyzed to develop a cohesive biomarker-based model based on cytometry expression profiles to improve IST selection for MDS patients.
Methods
Patients and Eligibility Criteria. This was a multicenter phase 2 clinical study. Detailed patient eligibility criteria is available in supplemental material. This trial (BMF RDCRN 5406) received institutional review board approval at all participating sites, and was registered at clinicaltrial.gov (NCT00466843).
Drug Administration.
Patients were hospitalized to receive r-ATG (Thymoglobulin®, Genzyme Corp) at a dose of 2.5 mg/kg/day intravenously (IV) for 4 doses (total 10 mg/kg). The daily infusion was administered over at least six hours and slowed as necessary to minimize infusion-related symptoms, as detailed in supplemental material.
All patients were pre-medicated with prednisone (1 mg/kg/day orally) two days prior to the first dose and during the infusion, and then continued on a tapering schedule of prednisone for 14 days after the final r-ATG dose to prevent serum sickness. Antibiotic prophylaxis was administered according to individual institutional practices. Protocol modifications are available in supplemental material.
Study Procedures:
Response evaluation was conducted at 16 weeks in Int-2 IPSS due to the possible risk of faster disease progression in unresponsive patients and 24 weeks in low/intermediate-1 IPSS risk patients. Patients were hospitalized for treatment and then followed on study weekly for the first month and then monthly until response evaluation. Baseline and on study complete blood counts with differential and chemistry were assessed. Blood product transfusions at baseline and on study were evaluated.
Bone marrow aspirate and biopsy was repeated at response evaluation.
Hematologic Response Criteria and Adverse Events. The primary endpoint was best HI for at least eight consecutive weeks according to the International Working Group (IWG) 2000 response criteria (18) . Patients who achieved HI were followed every six months for up to 2 years and annually thereafter. Disease progression (DP) was defined as outlined in supplemental material. Adverse events were graded according to the Common Toxicity Criteria of the National Cancer Institute (CTCAE version 3.0). Overall response, overall survival (OS), and progression free survival (PFS) are defined in supplemental material.
Study Design of the r-ATG Trial and Statistical Methods. A pre-defined accrual strategy was established for two cohorts based on IPSS classification. Specific information on the accrual goals and early stopping rules is available in the supplemental material. Clinical characteristics and adverse event data in patients treated with r-ATG were summarized using descriptive statistics, including mean, median, and range for continuous variables (e.g., age and duration of disease), and frequencies and percentages for categorical variables (e.g., gender and IPSS). Fisher's exact test was used to test any association of drug response and the discrete variables (e.g., IPSS).
The Spearman method was used to estimate correlation between continuous variables.
Univariate and multivariate analyses were performed using the Cox Proportional Hazards model. Kaplan Meier estimates for overall survival and log rank test were used for comparison. A detailed description of biomarker statistical analysis is provided in supplemental materials. hypotension and cardiac arrhythmias accompanied the infusion reaction in one patient.
One patient developed debilitating motor neuropathy that required prolonged hospitalization related to serum sickness from premature steroid withdrawal. Three deaths occurred on study including one patient with a preexisting line infection and one patient who experienced a complete response at the time of the event. One patient died of pulmonary aspergillosis.
Hematologic Response and Pretreatment Clinical
Response Co-variates in r-ATGtreated patients. Nine patients (33%, 95%CI=17%-54%) out of 27 in an intent-to-treat analysis had HI to r-ATG ( Table 3) . Erythroid response (n=7) included 6 major and 1 minor response. The median time to achieve a response was 75 days (range 3-114 days) and the median duration of response was 245 days (range 112 to >667 days). Of the ten patients with moderate-to-severe neutropenia (ANC median 0.275, range from 0 to 0.8), three had a sustained increase in neutrophils (30%) for 158 to 245 days at the date of censor and one patient continued to maintain the response at the last date of follow up. There were seven patients with thrombocytopenia defined as a platelet count <100 x 1,000/μL and five with profound thrombocytopenia (platelets <50 x 1,000/μL). Of these 13 thrombocytopenic patients, three had a sustained improvement in platelets.
Eighteen of 27 patients (66.7%) were non-responders and of these six (22%) were nonevaluable for response due to either study withdrawal (n=2), death related to infection (n=3), or study discontinuation due to infusion-related SAE (n=1). Twelve of the patients evaluated for response failed to have hematological improvement at either 16 or 24 week among whom 7 had stable disease and 5 had disease progression.
Pretreatment clinical variables were analyzed for association with hematologic improvement in the 21 patients that were evaluable for response (9 responders and 12 non-responders) ( Table 1) . Although younger age has emerged as a strong predictor for both survival and hematologic response to immunosuppressive therapy with e-ATG(1, 11), there was no age difference in responders and non-responders (p=1.0) using age as a continuous variable and using an age cut off of 61 years ( Table 4 ). The median time to achieve a response in patients was shown previously to be higher in both MDS and AA patients(19) compared to controls and significantly associated with e-ATG-response in MDS patients (1, 11) . Only four patients treated with r-ATG had the HLA-DR15 allele ( Table 4 ), but three of these patients achieved HI (75%). This difference was not statistically significant as a result of the small sample size. The time to achieve a response and the duration of response were similar in patients with and without the HLA-DR15 allele (data not shown). Of the three Int-2 category patients, two had a sustained improvement in platelets and neutrophil count for a median of 233.5 days (range 222 and 245 days), respectively, but subsequently relapsed and progressed to AML after a median of 509 (range 373 to 645)
days. Low and Int-1 responsive patients experienced no leukemia progression during the follow-up period. Several additional pretreatment variables failed to correlate with response in this study (Table 4) : ANC, platelet count, hemoglobin, lymphocyte count, bone marrow blast %, age-adjusted bone marrow cellularity (hypocellular, normal cellular, and hypercellular), IPSS, and M:E ratio. PNH phenotype, which has shown variable association with e-ATG response (20, 21) , was determined in fresh samples from 8 patients (4 responders and 4 non-responders) with no significant association to response.
Prolonged duration of RBC transfusion dependence (11) Table 2 ) to identify a novel profile with better accuracy for response classification. Of these immunological variables, CD8TM% (p=0.05, OR 1.09) and total CD4 Ki67% (p=0.02, OR 2.04) were significant classifiers independent of both age and disease duration. CD4/CD8 ratio (p=0.1) and %CD8 Ki67+ T-cells (p=0. 19) were not independent of age and disease duration in multivariable analyses so they were dropped from the final model (Supplemental Table 2 ). Using this multi-parameter classification, shorter disease duration (0.04, OR 15.89) and the immune profile (CD8 TM%, p=0.05 and CD4 Ki67%, 0.02) added value and were independent of age (p=0. 18) and drug treatment type (eATG versus rATG, p=0.33). Accuracy was tested using a LOOCV approach (Table 6) , as described previously (24) (25) (26) . Comparing the overall predictive accuracy of the multi-parameter biomarker model to age and disease duration by LOOCV, the final accuracy rate was 75.7% versus 59.5%, respectively. These results uniquely identify a signature that independently refines response estimates for ATG patient selection independent of drug treatment type and age (ie r-ATG or e-ATG).
Discussion
This prospective multicenter study shows that r-ATG has remitting activity in MDS comparable to that reported historically for e-ATG + cyclosporine(1 (14) , there was no difference in the observed response rates between these two treated groups. The hematologic improvement rate of 33% in this study is similar to reported rates of response to e-ATG treatment in unselected patients.
Patient selection criteria for e-ATG are currently based on a model from the NIH incorporating age, duration of transfusion dependence, and HLA-DR15. The effect of age has been the most important independent predictor of response to e-ATG with a lower probability of hematologic response in patients over the age of 60 yrs. When patients were stratified into younger (<61 yrs) and older (≥61 yrs) age groups in this study, there was no difference in the response rate (42.8% in both groups, p=1.0). In addition to age, hematologic improvement with e-ATG treatment in prior studies concluded that the HLA-DR15 class II genotype was also an independent covariate for response. Consistent with this finding, three of the four HLA-DR15 positive patients in this study responded to r-ATG (11). Including our study, a shorter interval between diagnosis and initiation of therapy has been associated with probability of response in four independent studies of patients treated with anti-lymphocyte serotherapy (11, 12, 14) Hematologic response rates, however, have shown an inconsistent relationship with bone marrow cellularity, PNH, and WHO classification (5, 21, 27, 28) .
In an effort to define a T-cell profile associated with ATG response independent of age or other covariates, we analyzed biomarkers in a mixed cohort of patients in this study. Several factors were significantly associated with hematologic improvement in univariate analyses. In a multivariate model, shorter disease duration, having a higher CD8TM% and a higher CD4+ T-cell proliferative index (Ki67+) independently discriminated response after adjusting for treatment type (e-ATG versus r-ATG), and age.
Longer duration of disease, number of prior therapies, and the presence of bone marrow fibrosis adversely affected response in r-ATG-treated patients. These may all jointly reflect a longer duration of immune-mediated bone marrow injury allowing for selection of clonal autonomy with an immune independent mechanism of clonal expansion. The precise mechanism underlying T-cell and immune deregulation is unknown, however, we previously reported a primary defect in telomerase function in naïve T-cells of MDS patients (29) . Failure to repair telomeres in rapidly expanding cells leads to premature growth arrest, apoptosis, cell exhaustion in stem cells and in lymphocytes, and T-cell repertoire alterations. These changes enhance the risk for autoimmune reactivity (30) (31) (32) . analyzed data, participated in study design, and wrote the manuscript. # Median of combined cohort is 23 months; CI=confidence interval; + OR=odds Ratio; TM=terminal memory, LOOCV**= leave-one-out cross validation; TM=terminal memory; rATG=rabbit anti-thymocyte globulin, eATG=equine anti-thymocyte globulin. Figures   Figure 1. Overall survival (OS) (A) and progression free survival (PFS) (B) after r-ATG therapy. Kaplan-Meier curves are shown for responders (red, n=9) and non-responders (black, n=18) to r-ATG in an intent-to-treat analysis.
Legend to
Supplemental Table 1 . Detailed patient characteristics of r-ATG and e-ATG-treated patients. the number of cytopenias, was used for pre-treatment risk stratification (18) . In addition, the bone marrow aspirate and biopsy were assessed for cellularity and fibrosis which was assessed in core biopsies stained for reticulin and graded by the modified European consensus scale as mild/none (score 0/1), moderate (score 2) or severe (score 3)(19).
All patients had bone marrow samples reviewed and diagnosis confirmed at the participating institutions. Peripheral blood samples for biomarker analysis were collected at least four weeks prior to initiation of therapy. Reduction in infusion rate for adverse events. The infusion rate was decreased to 50% for fever, chills, hypotension, dysrhythmia or itching with a maximum infusion length of 24 hours.
Detailed pre-defined accrual strategy and additional stopping rules. The Simon two-stage design was used to calculate sample size based on 80% power and 5% type I error based on two groups having an IPSS score of low/intermediate-1 (Int-1) Protocol modifications. The protocol was modified to include a chest X-ray at the screening visit to exclude occult pulmonary infection. Subjects with evidence of infection/infiltrate suspicious for active infection were ineligible until radiographic documentation of resolution.
Overall response, overall survival (OS), and progression free survival (PFS). The duration of overall response was determined from the time that hematologic response criteria were met until the first date that recurrent or progressive disease was objectively documented. Overall survival (OS) and progression free survival (PFS) were evaluated from the time of trial registration until either death or leukemia transformation, respectively. Patients were censored at the time of study withdrawal or event, where appropriate and analyses were performed using an intent-to-treat basis.
Sample collection and biomarker analysis. Pre-treatment peripheral blood samples on r-ATG-treated patients were collected on 17 of the 21 patients, as described in detail in supplemental Table 1 . Cryopreserved cells were stored in liquid nitrogen and analyzed at the end of the trial using 7-color flow cytometry, as described previously (20) . Frozen samples from 21 patients treated with e-ATG at the National Institutes of Health (NIH) or Cleveland Clinic were similarly analyzed. A description of the T-cell flow cytometry profiling methods is provided in supplemental material. Information about the e-ATG-treated patients is provided in Supplemental Table 1 .
Briefly, CD4 and CD8 T-cell immune profiles were detected after surface staining with anti-CD3-phycoerythrin (PE) Cy7, anti-CD45RA-FITC, anti-CD62L-APC and either anti-CD4− or CD8-APC Cy7 (BD Biosciences, San Jose, CA USA). The percentage of CD4+ and CD8+ cells in the CD3 gate was used to calculate the CD4/CD8 ratio. Naive and memory CD4 and CD8 T-cell populations were defined by CD45RA and CD62L expression as follows: naïve CD45RA+/CD62L+, central memory CD45RA-/CD62L+, effector memory CD45RA-/CD62L-, and terminal effector memory CD45RA+/CD62L-. 7, 8 A viability stain, 4′,6-diamindigo-Z-phenylinodole (DAPI) was used and results were analyzed on a LSRII Benchtop analyzer (BD Bioscience). Ki67 staining was performed on permeabilized cells using BD perm kit and the percentage of proliferating cells examined on naïve and memory as well as total CD3+/CD4+ and CD3+/CD8+ Tcells (20) . Exemplary primary dot plot data have been published previously. High resolution PNH testing was performed on freshly isolated blood samples by flow cytometry using liquid fluorescently labeled inactive toxin aerolysin (FLAER), as previously described, to quantify glycophosphatidylinositol (GPI)-anchor proteins (33) . A GPI-AP deficient (ie, PNH) phenotype was defined as FLAER-negative granulocytes ≥ 0.003% and FLAER-RBCs ≥ 0.005% (34) .
Definition of Disease Progression. Disease progression was defined by a  50% increase in myeloblasts, depending on baseline myeloblast percentage. For patients with <5% myeloblasts: an increase to >10% myeloblasts, or patients with 5% to 10% myeloblasts: 50% increase to >10% myeloblasts, and for patients with 10% to 20% myeloblasts: 50% increase to >20% myeloblasts. AML transformation was defined as  20% myeloblasts in the bone marrow or peripheral blood.
Detailed description of the statistical methods for biomarker analysis. T-cell profiling was examined using continuous data on a subset of patients with peripheral blood samples collected prior to treatment initiation. For biomarker studies, 17 r-ATGtreated patients contributed to this analysis. Data was also used from 21 patients treated with e-ATG at the National Heart, Lung, and Blood Institute (NHLBI). Response in this cohort has been published previously (1) . The accuracy rate of the final multivariable model was determined by the "leave-one-out" cross validation (LOOCV)
method. This approach used one patient as the validation data and the remaining patients as the training data each time and repeated the process from the 1 st patient to the last patient. At each process, the training data were used to build a multivariate model which was then used to predict response status of the patient from the validation data, as reported previously (22) (23) (24) . All tests were two-sided, with a p-value <0.05 determining significance.
